Daily Roundup

Change Financial Ltd is firing on all cylinders as it heads into the new financial year. The fintech company posted a positive net cash flow of A$0.3m in Q1 FY27, marking a significant milestone for the business. While overall revenue dipped slightly to A$6.3m due to lower one-off licence and professional services work, the company's core PaaS business is telling a different story entirely.

Platform-as-a-Service revenue hit a record A$3.2m, climbing 26% quarter-on-quarter, while active cards on the platform surged 92% in the same period. With two new PaaS clients already signed and four more in final contracting stages, Change is well-positioned for growth. The company remains confident about its full-year outlook, reconfirming guidance for net cash flow positive in FY27, and continues pushing forward with commercializing its Paysim product.

Resmed Inc has been busy on multiple fronts. The healthcare technology giant reported strong Q1 FY2027 results, with revenue climbing 6% to $1.4 billion—or 7% when adjusted for constant currency. Earnings per share impressed investors too, with GAAP diluted EPS jumping 23% to $2.92 and non-GAAP diluted EPS rising 14% to $2.91. The company's commitment to shareholder returns remained unwavering, with over $1 billion returned through buybacks and dividends during the quarter.

Looking ahead, Resmed guided for full-year FY2027 revenue between $5.75 billion and $5.85 billion, with non-GAAP diluted EPS expected to land between $12.00 and $12.25. The company also announced a dividend of USD 0.066 per share for CDI holders, payable on December 17, 2026. To manage the complexities of dual-listing logistics, Resmed deferred conversions between its US and Australian registers from November 11-12 to avoid inconsistent dividend entitlements—a technical but necessary housekeeping move.

Xreality Group Ltd is making serious inroads into the US market. The augmented reality company's customer base expanded to 132 globally, up 12% quarter-on-quarter and 65% year-on-year. Annual recurring revenue grew to $8.8m, increasing 10% QoQ and 46% YoY. The real headline, though, is Xreality's breakthrough with the US Marine Corps, which placed its first order for OP-2 Interceptor counter-drone training systems. Fresh contracts with Miami Beach Police, the Federal Reserve Bank, and the US Air Force's 36th Contracting Squadron in Guam signal genuine traction in the American defence and security sectors. On the home front, the company made a strategic pivot by exiting its entertainment VR business entirely, closing all FREAK venues to focus on its higher-margin professional solutions.

Coles Group Limited navigated a mixed quarter as Australia's retail landscape remains intensely competitive. Supermarkets sales grew 3.6% to $10.3 billion, buoyed by a stellar 22.9% surge in eCommerce penetration. Exclusive to Coles offerings performed particularly well, with Coles Finest sales jumping 13.3%. The Flybuys loyalty program showed renewed vigour, with swipe rates up 110 basis points and points redemptions climbing 16%. However, the liquor division stumbled with a 1.3% sales decline, though convenience formats showed promise. Coles flagged that cost-of-living pressures and aggressive competitor promotions continue to weigh on customer behaviour, but the company expects first-half Supermarkets EBIT to track in line with the prior year.

Clarity Pharmaceuticals Ltd is in a strong financial position to execute on its clinical pipeline. The biotech company holds A$152.9 million in cash, providing ample runway for its ambitious trials. The registrational Phase III CLARIFY trial has wrapped up recruitment and entered the patient follow-up phase, with topline data expected in the first half of 2027. Meanwhile, the SECuRE Phase I/IIa theranostic trial hit its recruitment target and delivered impressive early signals, with 74% of evaluable participants achieving PSA25. To bolster its commercialization push, Clarity appointed Michelle Hickey as Senior Vice President of Targeted Copper Theranostic Commercial Operations and welcomed Allison Rossiter to the board as an Independent Non-Executive Director.